Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for olmesartan medoxomil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00134160 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed Japan Heart Foundation Phase 4 2005-08-01 The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.
NCT00134160 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed OSCAR Study Phase 4 2005-08-01 The purpose of this study is to investigate whether high-dose angiotensin II receptor blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients not adequately controlled by standard dose ARB alone.
NCT00139698 Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Completed Pfizer Phase 3 2005-09-01 Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for olmesartan medoxomil

Condition Name

Condition Name for olmesartan medoxomil
Intervention Trials
Hypertension 26
Essential Hypertension 21
Healthy 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for olmesartan medoxomil
Intervention Trials
Hypertension 43
Kidney Diseases 4
Metabolic Syndrome X 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for olmesartan medoxomil

Trials by Country

Trials by Country for olmesartan medoxomil
Location Trials
United States 367
Germany 24
Netherlands 12
Mexico 11
Poland 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for olmesartan medoxomil
Location Trials
California 17
Florida 16
Texas 15
Ohio 15
North Carolina 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for olmesartan medoxomil

Clinical Trial Phase

Clinical Trial Phase for olmesartan medoxomil
Clinical Trial Phase Trials
Phase 4 22
Phase 3 34
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for olmesartan medoxomil
Clinical Trial Phase Trials
Completed 58
Recruiting 6
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for olmesartan medoxomil

Sponsor Name

Sponsor Name for olmesartan medoxomil
Sponsor Trials
Daiichi Sankyo Inc. 23
Daiichi Sankyo Europe, GmbH 9
Sankyo Pharma Gmbh 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for olmesartan medoxomil
Sponsor Trials
Industry 71
Other 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
McKinsey
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.